Seer Investor Relations Material
Seer, Inc. is a biotechnology company. It is engaged in the development and commercialization of products to decode the secret of the proteome. The company develops Proteograph Product Suite that enables researchers to understand and accelerate the progress of disease states. Seer, Inc. offers consumables, an automation instrumentation, and software components that are used in various proteomic studies such as drug discovery, clinical trials and other research applications. Its consumables are marketed under Proteograph brand name. Its automation instrumentation is marketed under ProteoLab brand name. It has collaboration agreements with life sciences organizations to offer its swab-free technology platform ParaGraph
Key slides for Seer Inc
Rubrik's 2024 IPO: What Investors Need To Know
Explore Rubrik's journey to a 2024 IPO, its innovative cybersecurity solutions, and strategic growth, highlighting its impact on the tech sector.
29 Feb 2024
Pricing Power Through Scarcity: A Case Study of Ferrari
Explore how Ferrari's scarcity and brand strength amplify its pricing power, crucial for a luxury company's success.
27 Feb 2024
Jacob Wallenberg: The Chairman of Investor AB
Get to know Jacob Wallenberg, one of the most influential businessmen in Europe and a part of the fifth generation of the Wallenberg family.
28 Feb 2024
🇺🇸 United States